Optimal sample sizes for phase II clinical trials and pilot studies
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Methodology for sample size calculation for phase III clinical trials is well established and widely used. In contrast, for earlier phase clinical trials or pilot studies, although there is an acceptance that the methods used for phase III trials are not appropriate, there is little consensus over methods that should be used. This paper explores this problem from a Bayesian decision‐theoretic perspective. The aim is to obtain sample sizes that would be appropriate for studies funded by a large funder such as a public sector body or major pharmaceutical company. The sample sizes obtained are optimal in that they minimise the average number of patients required per successfully identified effective therapy or equivalently maximise the number of effective therapies successfully identified over a long period. It is indicated that the number of patients included in a phase II clinical trial should be approximately 0.03 times that planned to be included in the phase III study. This is similar to that proposed by other researchers in this area, though rather smaller than actually used for many phase II trials. Copyright © 2011 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Decision Theory and Bayesian Analysis
Berger, J. O. (1985) · Springer Series in Statistics · doi:10.1007/978-1-4757-4286-2 · Cited by 7,722
Sample size of 12 per group rule of thumb for a pilot study
Julious, S. A. (2005) · Pharmaceutical Statistics · doi:10.1002/pst.185 · Cited by 3,068
Design and analysis of pilot studies: recommendations for good practice
Lancaster, G. A., Dodd, S., & Williamson, P. R. (2004) · Journal of Evaluation in Clinical Practice · doi:10.1111/j..2002.384.doc.x · Cited by 2,572
Research works printed but not linked: 17
- 10.2307/2530863 · doi:10.2307/2530863
- 10.1002/sim.4780050510 · doi:10.1002/sim.4780050510
- 10.1111/1541-0420.00047 · DOI
- 10.1002/pst.149 · DOI · Paper page
- 10.2307/2533060 · doi:10.2307/2533060
- 10.2307/2533868 · doi:10.2307/2533868
- 10.2307/2534011 · doi:10.2307/2534011
- 10.1111/j.1541-0420.2007.00951.x · doi:10.1111/j.1541-0420.2007.00951.x
- Smith JQ, 1988, Decision Analysis: A Bayesian Approach
- R Development Core Team, 2009, R: A Language and Environment for Statistical Computing
- 10.1081/SQA-200027049 · doi:10.1081/sqa-200027049
- 10.1214/lnms/1215451488 · DOI
- 10.2307/2534014 · DOI
- 10.1002/bimj.200510232 · DOI · Paper page
- 10.1002/bimj.200510231 · DOI · Paper page
- 10.1177/0962280210379035 · DOI
- 10.1016/0360-3016(80)90153-4 · DOI · Paper page
Cited by
CONSORT 2010 statement: extension to randomised pilot and feasibility trials.
Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., & Lancaster, G. A. (2016) · BMJ · doi:10.1136/bmj.i5239 · Cited by 3,404
“They may use accepted methods devised for phase II trials,[18] to assess the outcome to be used in a future phase III trial (which could be meta-analysed if required),[19] or use, “surrogate outcomes”, that is intermediate measures, often biochemical, which have less direct impact on a patient than, say, cure or death…”
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
on behalf of the PAFS consensus group, Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., & Lancaster, G. A. (2016) · Pilot and Feasibility Studies · doi:10.1186/s40814-016-0105-8 · Cited by 2,843
Billingham, S. A., Whitehead, A. L., & Julious, S. A. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-104 · Cited by 962
“Stallard [3] proposes that the sample size should be approximately 0.”
BackgroundGuidelines for designing and evaluating feasibility pilot studies
Teresi, J. A., Yu, X., Stewart, A. L., & Hays, R. D. (2022) · Medical Care · doi:10.1097/mlr.0000000000001664 · Cited by 734
A simple formula for the calculation of sample size in pilot studies
Viechtbauer, W., Smits, L., Kotz, D., Budé, L., Spigt, M., Serroyen, J., & Crutzen, R. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.04.014 · Cited by 612
Metadata
- Authors
- Stallard, N.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 2011-11-03
- Volume
- 31
- Issue
- 11-12
- Pages
- 1031-1042
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2024922049
- Cited by
- 116
- References
- 3
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.